Other reasons for permanent treatment discontinuation include life-threatening bradycardia without concomitant medication, treatment-related interstitial lung disease or pneumonitis, QTc interval prolongation accompanied with additional cardiovascular symptoms, and ALT/AST levels greater than three times the upper limit of normal (ULN) along with bilirubin levels greater than two times the ULN. This evidence concerns the gene GPT and interstitial lung disease.